Depomed Announces amount of U.
Depomed Announces amount of U.S. Patent for Gastric Retentive Gabapentin Dosage FormsDepomed announced that it is a Notice of Allowance from the U.S. Patent and Trademark Office received for pharmaceutical dosage forms that deliver the compound gabapentin addressed via proprietary Acufor Depomed the gastric retentive drug delivery technology.
Carl A. Depomed president and chief Executive Officer, added: ‘This new patent expands the patent portfolio around our extended release gabapentin formulation technology there are significant short-term developments upcoming covered both drug candidates through this patent Looking forward later to a regulatory filing for DM-1796 for the treatment of postherpetic neuralgia in. This quarter and the start of a Phase 3 trial for SeradaTM for the treatment of menopausal hot flashes early in the second quarter. ‘.The long-term effect of lifestyle interventions in order to diabetes in which of China prevented the Da Qing Diabetes Prevention Study:. , A 20 – year follow -up study G Li etal Lancet 371[ 9626]: pp. 1783 to 1789. Click here.